Additional file 1 of Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile

Additional file 1: Table S1. Characteristics of breast cancers from CHEK2 c.1100delC mutation carriers. Table S2. Number of variants, TMB, ID ratio, TP53 status, WGD, chromothripsis and percentage relative contribution of SBS, DSB, ID and SV signatures for primary and metastatic breast cancer genomes. Table S3. Relative contribution of major single base substitution signatures in primary and metastatic breast cancer genomes. Table S4. Relative contribution of major doublet base substitution signatures in primary and metastatic breast cancer genomes. Table S5. Relative contribution of major small indel signatures in primary and metastatic breast cancer genomes. Table S6. Relative contribution of 6 known structural variant signatures in CHEK2 versus HRD, ER− and ER+ primary breast cancer genomes. Table S7 Somatic driver gene mutation frequencies in primary and metastatic breast cancer genomes. Table S9. Genes differentially expressed between TP53 mutant and wild-type pBCs. Table S10. Clinicopathological variables of 760 ER+ lymph node negative treatment-naive breast cancer patients. Table S11. Clinicopathological variables of 323 hormone-naïve ER+ breast cancer patients treated with first-line tamoxifen for recurrent disease. Table S12. Univariable and multivariable Cox regression analysis of disease-free survival in 760 ER+ lymph node negative treatment-naive breast cancer patients. Table S13. Univariable and multivariable logistic regression analysis of overall response in 323 hormone-naïve ER+ breast cancer patients treated with first-line tamoxifen for recurrent disease. Table S14 Endocrine therapy resistance gene mutation frequencies in metastatic breast cancer genomes. Table S15. Sizes of structural variant types in primary and metastatic breast cancer genomes.